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Volume 48, Number 6 Letters to the Editor 1639We would like to emphasize that, according to American
College of Cardiology/American Heart Association (ACC/
AHA) guidelines, standard medical therapy of each patient with
peripheral atherosclerotic disease should include statins, if no
contraindication is present.1 Importantly, as shown by the
Reduction of Atherothrombosis for Continued Health
(REACH) registry, statins are underused in this patient popu-
lation.2 Besides the attenuation of AAA growth, statin treat-
ment improves long-term cardiac outcome of patients after
major vascular surgery, which is the predominant cause of late
mortality. In addition, statins also have a beneficial effect on the
early postoperative outcome. A meta-analysis by Hindler et al
showed that statin treatment was associated with a 59% reduc-
tion in overall short-term mortality after vascular surgery (1.7%
vs 6.1%; P  .0001),3 confirmed by the study of Feringa et al.4
In this study, statin users aged 65 years experienced a reduced
hospital mortality and long-term mortality after major non-
cardiac vascular surgery. In addition to survival benefits, statins
are also associated with a reduction in postoperative infections,5
improved recovery from acute kidney injury after major vascular
surgery,6 and improved preservation of renal function after
suprarenal aortic cross-clamping.7
We agree with the authors that a placebo-controlled ran-
domized trial cannot be justified anymore due to the continu-
ously growing evidence in literature of beneficial effects of
statins in patients with vascular diseases, including AAAs. Fu-
ture randomized trials may, however, improve treatment strat-
egies by comparing the effect of various statin therapies and
treatment targets on AAA growth rates and clinical outcomes in
patients with AAA.
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Regarding “Statins are independently associated with
reduced mortality in patients undergoing
infrainguinal bypass graft surgery for critical limb
ischemia”
Do statins save lives in patients undergoing infrainguinal by-
pass surgery for critical limb ischemia? Schanzer et al1 found that
the use of statin drugs was associated with a significant 1-year
survival benefit in patients undergoing surgical bypass grafting for
critical limb ischemia. However, the authors did not appear to
consider baseline cholesterol, as hypercholesterolemia is strikingly
related to statin use.1
It is well known that among hospitalized disabled older
adults, elevated levels of cholesterol are associated with an
increased rate of recovery from disability in basic activities of
daily living.2 On the other hand, in surgical patients, hypocho-
lesterolemia is a strong predictor of in-hospital death, nosoco-
mial infections, and length of hospital stay.3 Furthermore, in
patients undergoing general surgery, a low total cholesterol
level has been shown to be strongly associated with death after
2 years after discharge from the hospital.4
Curiously, a subgroup analysis of the Heart Protection Study
focusing on patients with peripheral artery disease5 failed to con-
sider mortality data by combining deaths with aneurysm repairs.
They found a small increase among those randomized to simvasta-
tin for this combined end point.5 Therefore, it is highly plausible
that in the study by Schanzer et al,1 statin use selected the healthy
statin user or unselected the unhealthy low-cholesterol patient.
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Reply
We appreciate the interest of the readers above in our study
analyzing the association of statins with mortality after infraingui-
nal bypass in patients with critical limb ischemia. Their insightful
comments point to a weakness inherent to all nonrandomized
studies—propensity score models or multivariable regression mod-
els can only control for measured confounders and not unmea-
sured confounders. Our study did not control for cholesterol
levels, because these values were not available from our source data
(the PREVENT III trial).
While we agree with the readers that there is a small body of
literature, primarily pertaining to general surgery, that has sug-
gested a potential benefit to hypercholesterolemia, this effect has
yet to be demonstrated in patients with peripheral arterial disease.
Nonetheless, our data do not allow us to refute the comments of
the readers above—it is possible that, in our study, some of the
mortality benefit that was attributed to the use of statins may have
been affected by concurrent hypercholesterolemia in the patient
group on statin therapy.
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Carotid artery stenting: a promising therapeutic
option for carotid artery stenosis or a bubble about
to burst?
A recent prospective randomized trial compared for the first
time the long-term results of carotid endarterectomy (CEA) with
carotid artery stenting (CAS) (median observation time: 64 12.1
months vs. 66  12.1 months, respectively).1 This study showed
that CEA is superior to CAS with respect to stroke (0 of 42 vs. 4 of
42, respectively),70% restenosis (0 of 29 vs. 6 of 32, respectively)
and re-intervention rates (0 of 29 vs. 5 of 32, respectively; for all
associations P  .05).1
Two issues may hamper the interpretation of the results of this
study:1 first, CAS was performed without the use of embolic
protecting devices (EPDs).1 Although the exact role of EPDs in
CAS has not yet been established, their use may offer considerable
advantages. For example, a large (n  1,483 patients), multi-
center (n 26 hospitals), randomized study comparing CAS with
vs. without EPDs demonstrated that, compared with non-use, the
use of EPDs during CAS was associated with lower ipsilateralstroke (4.1% vs. 1.7%, respectively; P  .007) and lower non-fatal
stroke and death rates (4.9% vs. 2.1%, respectively; P  .004).2
Opposing results were reported in a recent prospective random-
ized study comparing the incidence of embolic lesions during CAS
with vs. without EPDs;3 the use of EPDs during CAS did not
reduce the number of emboli (average number of embolic lesions:
6.1 vs. 6.2, respectively; P  .79).3 A possible explanation for this
lack of difference may be the small size of CAS procedures included
(n  36).3
A second drawback is the early recruitment period (August
1999 to April 2002).1 Since then, the technique of CAS has
evolved considerably; new, better-designed, and improved stent
models have been introduced and employed. Additionally, physi-
cians have gradually become more experienced; a study presenting
a detailed analysis of periprocedural complications of CAS demon-
strated the importance of an appropriate learning curve before
systematic use of CAS.4 Thus, it could be expected that a similar
study performed today might produce different results than the
ones reported.1
The role of CAS in the treatment of carotid artery stenosis is
still the subject of extensive debate. Current evidence suggests that
it may still be premature to attempt to draw definite conclusions.
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Reply
Thank you for the opportunity to respond to the letter con-
cerning our article “Alert for increased long-term follow-up after
carotid artery stenting: Results of a prospective, randomized, single-
center trial of carotid artery stenting vs carotid endarterectomy.”
Carotid endarterectomy (CEA) or carotid artery stenting
(CAS) in symptomatic patients is performed to reduce the risk of
secondary stroke or stroke-related death. Therefore, the main
focus of this article was the evaluation of restenosis, secondary
stroke rate, and death in a long-term follow-up of a prospective,
randomized study of CEA vs CAS.
We understand the concern that embolic protection devices
(EPD) might reduce peri-interventional stroke rates after CAS.
However, the cited publication1 is not a randomized study but
rather a registry from multiple cardiology centers during 1998 to
2003. The use of embolic protection devices (EPD) increased over
